New COVID-19 Immunology Data Available in ImmPort

A primary mission of ImmPort is to promote rapid availability of data associated with important findings via a trusted open access platform. ImmPort’s latest release of data contains high-quality immunological findings related to COVID-19, as well as other significant studies in the field of immunology. Studies shared during this data release include:

• SDY1655 Longitudinal Analyses Reveal Immunological Misfiring in Severe COVID-19, PI: Akiko Iwasaki - Yale School of Medicine

• SDY1648 Sex Differences in Immune Responses to SARS-CoV-2 that Underlie Disease Outcomes, PI: Akiko Iwasaki - Yale School of Medicine

• SDY1640 Targets of T Cell Responses to SARS-Cov-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals, PI: Alessandro Sette - La Jolla Institute for Immunology

• SDY1662 An Inflammatory Cytokine Signature Predicts Covid-19 Severity and Survival, PI: Sacha Gnjatic - Icahn School of Medicine at Mount Sinai

• SDY1630 Effects of Tissue Localization on Natural Killer Cell Phenotypic and Functional Diversity, PI: Donna Farber - Columbia University

• SDY1634 Charge-altering Releasable Transporters Enable Specific Phenotypic Manipulation of Resting Primary Natural Killer Cells, PI: Catherine Blish – Stanford University

• SDY1603 Investigating the Natural Killer Cell Response to Acute Dengue Infection in Adult and Pediatric Patients; PI: Catherine Blish - Stanford University; Sandra López-Vergès - Gorgas Memorial Institute for Health Studies

• SDY1654 Single-cell Transcriptomics of Human T Cells Reveals Tissue and Activation Signatures in Health and Disease, PI: Donna Farber - Columbia University

• SDY1434 Steroid and Tacrolimus Avoidance Using NULOJIX (Belatacept) in Renal Transplantation, PI: Kenneth Newell - Emory University

• SDY1633 An Open-label, First-in-human, Safety and Pharmacokinetic Study of One-month Sustained-release Injectable Tacrolimus in Healthy Subjects, PI: George Atiee - Worldwide Clinical Trials

For a detailed listing of all studies shared or updated through ImmPort’s latest release, please see ImmPort’s Data Release Notes.

New to ImmPort? Registration is quick, simple, and free. ImmPort is sponsored by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Disease (NIAID) and is a recommended data repository by PLOS One, Nature’s Scientific Data, and holds the Core Trust Seal of Approval for Core Trustworthy Data Repositories.